WO2022250385A1 - Composition contenant un dérivé de macrolactine ou un sel de qualité pharmaceutique de celui-ci en tant que principe actif pour la prévention ou le traitement d'une maladie infectieuse causée par le virus de la fièvre aphteuse - Google Patents

Composition contenant un dérivé de macrolactine ou un sel de qualité pharmaceutique de celui-ci en tant que principe actif pour la prévention ou le traitement d'une maladie infectieuse causée par le virus de la fièvre aphteuse Download PDF

Info

Publication number
WO2022250385A1
WO2022250385A1 PCT/KR2022/007241 KR2022007241W WO2022250385A1 WO 2022250385 A1 WO2022250385 A1 WO 2022250385A1 KR 2022007241 W KR2022007241 W KR 2022007241W WO 2022250385 A1 WO2022250385 A1 WO 2022250385A1
Authority
WO
WIPO (PCT)
Prior art keywords
macrolactin
foot
bacillus
accession number
mouth disease
Prior art date
Application number
PCT/KR2022/007241
Other languages
English (en)
Korean (ko)
Inventor
강재선
정재훈
강효린
김형회
박민희
황성우
이승재
황예진
김현우
최시훈
Original Assignee
경성대학교 산학협력단
주식회사 에이아이인사이트
부산대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경성대학교 산학협력단, 주식회사 에이아이인사이트, 부산대학교 산학협력단 filed Critical 경성대학교 산학협력단
Publication of WO2022250385A1 publication Critical patent/WO2022250385A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A23K20/126—Lactones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/195—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Definitions

  • the present invention relates to a composition for preventing or treating foot-and-mouth disease virus infection comprising a macrolactin derivative.
  • foot-and-mouth disease breaks out, productivity of animals (pigs, cows, sheep, goats, etc.) is reduced and infected animals are slaughtered, which not only reduces the profits of farmhouses due to the reduction or restriction of sales and exports, but also the environment caused by animal slaughter.
  • An issue is emerging.
  • the foot-and-mouth disease virus can spread through the air to distant areas in a short time, so there is a problem that the speed of killing does not keep up with the speed of virus propagation.
  • ICK-DONG YOO actinomadura sp. MA was isolated from the strain, and studies were conducted on the protection of neurons induced by glutamate using the isolated MA.
  • Hiroshi Sano discovered Bacillus. sp. MA was isolated from strain PP19-H3 and its antibacterial activity against strains Staphylococcus aureus IFO 12732 and Bacillus subtilis IFO 3134 was studied.
  • macrolactin-type compounds have various pharmacological activities as described above, there is no research report on their pharmacological activity against foot-and-mouth disease.
  • An object of the present invention is to provide a composition for preventing or treating foot-and-mouth disease virus infectious diseases comprising a macrolactin derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Another object of the present invention is to provide a feed additive for preventing or improving foot-and-mouth disease virus infection disease comprising a macrolactin derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the term "administration" means introducing the pharmaceutical composition or feed composition of the present invention to a subject by any suitable method.
  • the route of administration may be oral or parenteral administration through any general route as long as it can reach the target tissue.
  • it can be administered by any device that allows the pharmaceutical composition or feed additive of the present invention to move to target cells.
  • the pharmaceutical composition may be added in an amount of preferably 0.001 to 50% by weight, more preferably 0.001 to 40% by weight, and most preferably 0.001 to 30% by weight based on the total weight of the total composition.
  • the pharmaceutical composition of the present invention can be administered to mammals such as rats, livestock, and humans through various routes. All modes of administration can be envisaged, for example by intravenous, intramuscular, subcutaneous, intrauterine intrathecal or intracerebrovascular injection and dermal application. Since the composition of the present invention has little toxicity and side effects, it can be safely used even when taken for a long period of time for preventive purposes.
  • the present invention provides a veterinary pharmaceutical composition for preventing or treating foot-and-mouth disease virus infection, comprising a macrolactin derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention provides a pharmaceutical composition for animals for preventing or treating foot-and-mouth disease virus infection disease comprising a macrolactin derivative or a veterinarily acceptable salt thereof as an active ingredient.
  • the feed additive of the present invention includes what is added to feed, and refers to a feed additive that can prevent, treat, or improve diseases caused by foot-and-mouth disease virus infection or foot-and-mouth disease virus in addition to existing additives.
  • Foot-and-mouth disease is transmitted through direct contact through the blister fluid, saliva, milk, semen, respiratory air, or feces of infected animals.
  • indirect infection is possible through the work clothes, gloves, shoes, vehicles, and feed of farm owners, farm workers, veterinarians, artificial insemination workers, feed suppliers, manure handlers, and slaughterhouse delivery vehicle drivers. Not only that, but it can also be transmitted through the air.
  • the feed composition of the present invention has excellent antiviral efficacy, thereby increasing resistance and defense ability against virus-related diseases, thereby preventing mortality and productivity reduction caused by virus-related diseases, thereby preventing human infection.
  • the pharmaceutical composition or feed composition of the present invention may further contain at least one active ingredient exhibiting the same or similar efficacy in addition to the macrolactin derivative or a pharmaceutically acceptable salt thereof.
  • the incubation temperature was 30 °C and the agitation speed was 1 VVM. Acidity was adjusted to pH 6.8. A small amount of the fermentation broth was aseptically aliquoted twice a day and used in the experiment. After culturing, each strain was collected after 0.5, 0.78, 1, 1.5, 1.8, 2.3, 2.5, 3.2, 3.5 and 4.2 days and the culture medium was analyzed. The collected culture medium of each strain was centrifuged to take the supernatant, and after mixing the same volume of Ethyl-acetate (EA), EA of about 50% by volume was collected and concentrated under reduced pressure. The concentrate was dissolved in methanol and analyzed using LC/Mass.
  • EA Ethyl-acetate
  • the analytical instrument was an Agilent 1100 high-pressure liquid chromatography, and the detector was an online diode array detector (DAD). Analysis conditions used an Agilent mass selective detector (MSD) with an electrospray ionization device in positive or negative mode.
  • MSD mass selective detector
  • the column used was an A Zorbax SB C18 column (dimensions, 250 by 4.6 mm), and the flow rate was 1 ml/min.
  • the analysis wavelength was UV 262 nm, and acetonitrile (ACN) containing 0.1% formic acid and purified water were used as the mobile phase.
  • the concentration of ACN was used by constantly increasing the concentration from 0% to 100% for 20 minutes. As needed, it was analyzed while maintaining a constant 40% concentration.
  • the first peak a], the second peak b], and the third peak c] separated by MPLC were further analyzed by HPLC, and the results are shown in FIG. 4 .
  • a) is the sample in a mixture state
  • b) is the first peak
  • c) is the second peak
  • d) is the third peak analysis result.
  • Bacillus velezensis KJS-4 was cultured using a medium containing sterilized 5% HP-20 resin (v/v %). This is because it uses the property of adsorbing to HP-20.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition contenant un dérivé de macrolactine ou un sel de qualité pharmaceutique de celui-ci en tant que principe actif pour la prévention ou le traitement d'une maladie infectieuse causée par le virus de la fièvre aphteuse. La composition est indiquée pour inhiber l'expression génique du virus de la fièvre aphteuse et ainsi inhiber la prolifération du virus de la fièvre aphteuse, ce qui permet de s'attendre à ce qu'elle puisse lutter efficacement contre la propagation de la fièvre aphteuse.
PCT/KR2022/007241 2021-05-24 2022-05-20 Composition contenant un dérivé de macrolactine ou un sel de qualité pharmaceutique de celui-ci en tant que principe actif pour la prévention ou le traitement d'une maladie infectieuse causée par le virus de la fièvre aphteuse WO2022250385A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0066415 2021-05-24
KR1020210066415A KR102671165B1 (ko) 2021-05-24 2021-05-24 마크로락틴 유도체, 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 구제역 바이러스의 감염 질환 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
WO2022250385A1 true WO2022250385A1 (fr) 2022-12-01

Family

ID=84229018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/007241 WO2022250385A1 (fr) 2021-05-24 2022-05-20 Composition contenant un dérivé de macrolactine ou un sel de qualité pharmaceutique de celui-ci en tant que principe actif pour la prévention ou le traitement d'une maladie infectieuse causée par le virus de la fièvre aphteuse

Country Status (2)

Country Link
KR (1) KR102671165B1 (fr)
WO (1) WO2022250385A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101070324B1 (ko) * 2009-05-22 2011-10-06 대우제약 주식회사 마크로락틴 에이 및 그 유도체를 유효성분으로 함유하는 항염제 조성물
KR20140016212A (ko) * 2013-12-19 2014-02-07 한국해양과학기술원 항균활성을 가지는 신규의 마크로락틴류를 생성하는 해양 미생물, 이 해양 미생물로부터 생성된 신규의 마크로락틴류 및 이 마크로락틴의 제조방법
CN105126096A (zh) * 2015-09-08 2015-12-09 吕宏亮 一种口蹄疫病毒样颗粒疫苗及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653933C (fr) 2006-05-31 2013-10-08 Toyama Chemical Co., Ltd. Agent anti-virus de la fievre aphteuse pour un animal appartenant a la famille des suides ou pour un mouton, et procede pour la prevention ou le traitement de la fievre aphteuse chez un animal appartenant a la famille des suides ou chez un mouton
KR101381344B1 (ko) 2013-12-19 2014-04-25 한국해양과학기술원 항균활성을 가지는 신규의 마크로락틴류를 생성하는 해양 미생물, 이 해양 미생물로부터 생성된 신규의 마크로락틴류 및 이 마크로락틴의 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101070324B1 (ko) * 2009-05-22 2011-10-06 대우제약 주식회사 마크로락틴 에이 및 그 유도체를 유효성분으로 함유하는 항염제 조성물
KR20140016212A (ko) * 2013-12-19 2014-02-07 한국해양과학기술원 항균활성을 가지는 신규의 마크로락틴류를 생성하는 해양 미생물, 이 해양 미생물로부터 생성된 신규의 마크로락틴류 및 이 마크로락틴의 제조방법
CN105126096A (zh) * 2015-09-08 2015-12-09 吕宏亮 一种口蹄疫病毒样颗粒疫苗及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BELLO, T.R. ALLEN, T.: "The use of MicroLactin for inflammatory conditions in Equine Veterinary practice", JOURNAL OF EQUINE VETERINARY SCIENCE, vol. 25, no. 9, 1 September 2005 (2005-09-01), US , pages 380 - 382, XP005198664, ISSN: 0737-0806, DOI: 10.1016/j.jevs.2005.08.004 *
M. ROMERO-TABAREZ, JANSEN R., SYLLA M., LUNSDORF H., HAUSSLER S., SANTOSA D. A., TIMMIS K. N., MOLINARI G.: "7-O-Malonyl Macrolactin A, a New Macrolactin Antibiotic from Bacillus subtilis Active against Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococci, and a Small-Colony Variant of Burkholderia cepacia", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 50, no. 5, 1 May 2006 (2006-05-01), pages 1701 - 1709, XP055023677, ISSN: 0066-4804, DOI: 10.1128/AAC.50.5.1701-1709.2006 *

Also Published As

Publication number Publication date
KR102671165B1 (ko) 2024-06-03
KR20220158512A (ko) 2022-12-01

Similar Documents

Publication Publication Date Title
WO2014133323A1 (fr) Nouveau bactériophage et composition antibactérienne le comprenant
WO2014133322A1 (fr) Nouveau bactériophage et composition antibactérienne comprenant celui-ci
WO2015160089A1 (fr) Nouveau bactériophage, et composition le contenant
WO2010074388A1 (fr) Nouveau bactériophage et compositions antibactériennes comprenant celui-ci
WO2020050460A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement de maladies intestinales inflammatoires
WO2014133289A1 (fr) Nouveau bactériophage et composition antibactérienne le comprenant
US5135746A (en) Control of protozoal disease
WO2015156509A1 (fr) Nouveau bactériophage et composition le contenant
EP2961832A1 (fr) Nouveau bactériophage et composition antibactérienne comprenant celui-ci
WO2014133301A1 (fr) Nouveau bactériophage et composition antibactérienne le comprenant
KR102597757B1 (ko) 천연물 유래 화합물 및 이를 유효성분으로 함유하는 항바이러스제
WO2017086608A1 (fr) Composition pour prévenir ou traiter des maladies osseuses et des maladies articulaires, contenant, en tant que substances actives, un complexe de calcium ionisé hydrosoluble et de fructo-oligosaccharide
KR101658048B1 (ko) 포스파티딜콜린 합성경로 관여 물질을 포함하는 항바이러스용 조성물
WO2022071718A1 (fr) Nouveau bactériophage opt-sc01 spécifique de bactéries staphylococcus et composition antibactérienne le comprenant
WO2020076043A1 (fr) Bactéries du microbiote intestinal présentant un effet prophylactique ou thérapeutique contre la dépression, et utilisation correspondante
WO2011155727A2 (fr) Méthode de prévention et de traitement d'une infection provoquée par salmonella choleraeuis ou salmonella dublin
WO2022250385A1 (fr) Composition contenant un dérivé de macrolactine ou un sel de qualité pharmaceutique de celui-ci en tant que principe actif pour la prévention ou le traitement d'une maladie infectieuse causée par le virus de la fièvre aphteuse
KR102573565B1 (ko) 플라보노이드 계열 화합물 및 이를 유효성분으로 함유하는 항바이러스제
KR100866021B1 (ko) 돼지와 가금의 질병 및 감염 치료 및 예방용 조성물
WO2015160164A1 (fr) Nouveau bactériophage et composition le comprenant
WO2012093855A2 (fr) Nouveau composé de flavimycine, composition antifongique le contenant et leur procédé de production
WO2015065059A1 (fr) Composition pour prévenir ou traiter une septicémie hémorragique virale chez les poissons comprenant un extrait d'ecklonia cava
WO2012118287A2 (fr) Nouveau composé isolé à partir d'ail chinois, et utilisation de celui-ci en tant qu'agent antiviral
WO2018030857A1 (fr) Composition antivirale contenant un extrait de racine de panax notoginseng
JPH08205856A (ja) 抗生物質ＬＬ−Ｅ１９０２０αおよびβの産生菌

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22811578

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22811578

Country of ref document: EP

Kind code of ref document: A1